Amfetamine extended-release (liquid suspension)- Neos Therapeutics

Drug Profile

Amfetamine extended-release (liquid suspension)- Neos Therapeutics

Alternative Names: Adzenys ER; AMP XR OS; Amphetamine extended-release oral suspension; Amphetamine XR-liquid suspension; Amphetamine XR-suspension - Neos Therapeutics; Extended release amphetamine liquid suspension - Neos Therapeutics; NT-0201

Latest Information Update: 15 Jan 2018

Price : *
* Final gross price and currency may vary according to local VAT and billing address.
* Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase. A link to download a PDF version of the drug profile will be included in your email receipt. Adis is an information provider. We do not sell or distribute the pharmaceutical compounds written about in this database.

At a glance

  • Originator Neos Therapeutics
  • Class Amphetamines; Small molecules
  • Mechanism of Action Adrenergic receptor agonists; Central nervous system stimulants; Trace amine-associated receptor 1 agonists
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity No

Highest Development Phases

  • Registered Attention-deficit hyperactivity disorder

Most Recent Events

  • 10 Jan 2018 Amfetamine extended-release is not yet launched for Attention-deficit hyperactivity disorder in USA (PO) (literature review)
  • 22 Nov 2017 Neos Therapeutics initiates enrolment in a phase I trial for Attention-deficit hyperactivity disorder in USA (Before November 2017)
  • 26 Oct 2017 The US label for amphetamine extended release oral suspension carries a black box warning related to the potential for abuse and dependence
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top